ArticleChemistry (Weinheim an der Bergstrasse, Germany)2025
Double-Click Strategy Combining CuAAC and (Thia-) Diels-Alder Reactions; Application Toward Peptide Labeling.
Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
We report an efficient double-click strategy combining copper-catalyzed azide-alkyne cycloaddition (CuAAC) with (thia-)Diels-Alder (DA) reactions, enabled by newly designed heterobifunctional platforms bearing orthogonal clickable groups: alkyne-dithioester, alkyne-maleimide, or azide-diene. These platforms were evaluated through both one-pot sequential protocols (CuAAC/DA or CuAAC/thia-DA) and three-component reactions (3CR), using model substrates with complementary functionalities. The use of a highly reactive s-cis-constrained exocyclic diene, enabled rapid cycloadditions with maleimide or phosphonodithioester dienophiles. All reactions were performed under mild, biocompatible conditions (37 °C, 1:1 H₂O/iPrOH, 1-2 hours), and most afforded the desired conjugates in good isolated yields. The methodology was further validated through the successful bioconjugation of three small peptides with either a fluorophore or biotin, demonstrating its efficiency, versatility, and compatibility with biologically relevant functional groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.